Suzetrigine: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = 477002123 | | verifiedrevid = 477002123 | ||
| IUPAC_name = 1-(2,3-dichlorophenyl)-4-methyl-5H- | | IUPAC_name = 1-(2,3-dichlorophenyl)-4-methyl-5H-dibenz[b,f]azepine-5-carboxamide | ||
| image = Suzetrigine.svg | | image = Suzetrigine.svg | ||
| image2 = Suzetrigine_3D_structure.png | | image2 = Suzetrigine_3D_structure.png | ||
}} | }} | ||
'''Suzetrigine''' is a chemical compound that has been investigated for its potential use as an [[anticonvulsant]] medication. It belongs to | '''Suzetrigine''' is a chemical compound that has been investigated for its potential use as an [[anticonvulsant]] medication. It belongs to the class of [[dibenzazepine]] derivatives, which are known for their activity in the central nervous system. | ||
==Chemical Structure== | ==Chemical Structure== | ||
[[File:Suzetrigine.svg|Chemical structure of Suzetrigine|thumb| | [[File:Suzetrigine.svg|Chemical structure of Suzetrigine|thumb|right]] | ||
Suzetrigine is characterized by its | Suzetrigine is characterized by its dibenzazepine core, which is a tricyclic structure. The compound is further modified with a carboxamide group and two chlorine atoms on the phenyl ring, contributing to its pharmacological properties. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
The exact mechanism of action of suzetrigine is not fully understood, | The exact mechanism of action of suzetrigine is not fully understood. However, like other anticonvulsants, it is believed to modulate the activity of [[ion channels]] in the brain, particularly those involved in the propagation of [[action potentials]]. This modulation helps stabilize neuronal membranes and prevent the excessive firing that leads to seizures. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
Suzetrigine is absorbed | Suzetrigine is absorbed in the gastrointestinal tract when administered orally. It undergoes hepatic metabolism, and its metabolites are excreted primarily through the kidneys. The pharmacokinetic profile of suzetrigine, including its half-life and bioavailability, is crucial for determining appropriate dosing regimens in clinical settings. | ||
==Clinical | ==Clinical Use== | ||
While suzetrigine has shown promise in preclinical studies, it is not currently approved for clinical use. Research continues to evaluate its efficacy and safety in the treatment of [[epilepsy]] and other seizure disorders. | |||
== | ==Side Effects== | ||
Potential side effects of suzetrigine, as with other anticonvulsants, may include dizziness, drowsiness, and gastrointestinal disturbances. Long-term use may require monitoring of liver function and blood cell counts. | |||
==Research and Development== | ==Research and Development== | ||
Research | [[File:Suzetrigine_3D_structure.png|3D structure of Suzetrigine|thumb|left]] | ||
Research on suzetrigine is ongoing, with studies focusing on its pharmacodynamics, potential therapeutic applications, and comparison with existing anticonvulsant drugs. The development of suzetrigine is part of a broader effort to find more effective treatments for epilepsy with fewer side effects. | |||
==Related Pages== | ==Related Pages== | ||
* [[Anticonvulsant]] | * [[Anticonvulsant]] | ||
* [[ | * [[Epilepsy]] | ||
* [[Dibenzazepine]] | |||
* [[Ion channel]] | * [[Ion channel]] | ||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
[[Category: | [[Category:Dibenzazepines]] | ||
Latest revision as of 01:34, 7 March 2025
Anticonvulsant drug
| Suzetrigine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Suzetrigine is a chemical compound that has been investigated for its potential use as an anticonvulsant medication. It belongs to the class of dibenzazepine derivatives, which are known for their activity in the central nervous system.
Chemical Structure[edit]
Suzetrigine is characterized by its dibenzazepine core, which is a tricyclic structure. The compound is further modified with a carboxamide group and two chlorine atoms on the phenyl ring, contributing to its pharmacological properties.
Mechanism of Action[edit]
The exact mechanism of action of suzetrigine is not fully understood. However, like other anticonvulsants, it is believed to modulate the activity of ion channels in the brain, particularly those involved in the propagation of action potentials. This modulation helps stabilize neuronal membranes and prevent the excessive firing that leads to seizures.
Pharmacokinetics[edit]
Suzetrigine is absorbed in the gastrointestinal tract when administered orally. It undergoes hepatic metabolism, and its metabolites are excreted primarily through the kidneys. The pharmacokinetic profile of suzetrigine, including its half-life and bioavailability, is crucial for determining appropriate dosing regimens in clinical settings.
Clinical Use[edit]
While suzetrigine has shown promise in preclinical studies, it is not currently approved for clinical use. Research continues to evaluate its efficacy and safety in the treatment of epilepsy and other seizure disorders.
Side Effects[edit]
Potential side effects of suzetrigine, as with other anticonvulsants, may include dizziness, drowsiness, and gastrointestinal disturbances. Long-term use may require monitoring of liver function and blood cell counts.
Research and Development[edit]
Research on suzetrigine is ongoing, with studies focusing on its pharmacodynamics, potential therapeutic applications, and comparison with existing anticonvulsant drugs. The development of suzetrigine is part of a broader effort to find more effective treatments for epilepsy with fewer side effects.
